8-K: Eledon Pharma Issues Pre-Funded Warrants in Equity Exchange

Eledon Pharmaceuticals exchanged 4,203,764 common shares for pre-funded warrants with Coastlands Capital Partners LP, restructuring an existing equity position.

Summary

• Eledon Pharmaceuticals, Inc. entered into an exchange agreement with Coastlands Capital Partners LP on December 30, 2025.
• Coastlands Capital Partners LP exchanged 4,203,764 shares of Eledon's common stock for a pre-funded warrant to purchase up to 4,203,764 shares of common stock.
• The pre-funded warrant has an initial exercise price of $0.001 per share, with the aggregate exercise price (minus this nominal amount) having been pre-funded to the company.
• The warrant is immediately exercisable and remains so until fully exercised.
• The transaction was conducted under Section 3(a)(9) of the Securities Act, meaning it was an exchange with existing security holders without new consideration or commissions.

Sentiment

Score: 7

Explanation: The transaction is a neutral to slightly positive capital structure adjustment. It involves the company effectively repurchasing shares from a holder via an exchange for a pre-funded warrant, which can be anti-dilutive. The 'pre-funded' nature means the company has already received the capital. While not a direct operational positive, it reflects a managed approach to equity holdings and beneficial ownership.

Positives

• The company effectively repurchased 4,203,764 shares of its common stock from Coastlands Capital Partners LP, which can be anti-dilutive for other shareholders.
• The 'pre-funded' nature of the warrant means the company has already received the economic value for the shares underlying the warrant, without requiring new cash outflow for the repurchase.
• The transaction provides flexibility for the holder to manage beneficial ownership limits while retaining the right to acquire shares.

Negatives

• The complexity of the transaction structure may require careful interpretation by investors.
• Potential for future dilution if the warrants are exercised and the shares are re-issued, although the capital for these shares was already received by the company.

Risks

• The holder's beneficial ownership is limited to 4.99% (or 9.99% with notice, up to 19.99% with Nasdaq approval) of outstanding common stock immediately after exercise, which could restrict immediate full exercise.
• Fluctuations in the company's common stock price (VWAP or Bid Price) will affect the value received in a cashless exercise.
• Failure by the company to timely deliver warrant shares upon exercise could result in liquidated damages and buy-in compensation for the holder.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's operational or financial performance, beyond the mechanics of the warrant's future exercise.

Management Comments

• The Company agrees not to take any position contrary to this Section 3(c).
• The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
• The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.

Industry Context

This transaction represents a capital structure adjustment for Eledon Pharmaceuticals, common in the biotechnology and pharmaceutical sectors for managing shareholder positions, beneficial ownership, or optimizing capital allocation. It does not directly reflect broader industry trends in drug development or market performance but rather a financial engineering move.

Corporate Governance

Related Party Transactions

• The exchange agreement is between Eledon Pharmaceuticals, Inc. and Coastlands Capital Partners LP, a significant holder of the company's securities.

Stakeholder Impact

• Shareholders: The effective repurchase of 4,203,764 shares from Coastlands Capital Partners LP could be anti-dilutive for other existing shareholders. Future exercise of the warrants would re-issue these shares, but the capital is already received.
• Coastlands Capital Partners LP (Holder): Gains flexibility in managing its beneficial ownership percentage while retaining the right to acquire the underlying shares at a nominal exercise price.

Next Steps

• The holder may exercise the pre-funded warrant, in whole or in part, at any time until fully exercised.
• The company will ensure sufficient authorized and unissued common stock is reserved for warrant exercise.
• The company will provide notice to the holder regarding adjustments to the exercise price or significant corporate actions affecting common stock.

Key Dates

Recommendation

This filing details a technical capital structure adjustment where a significant holder exchanged common stock for pre-funded warrants. While the effective repurchase of shares can be seen as a positive, it doesn't provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The transaction primarily offers flexibility to the holder and manages beneficial ownership, suggesting a 'hold' as investors await further operational updates.

Keywords

Eledon Pharmaceuticals, ELDN, Pre-Funded Warrant, Equity Exchange, Common Stock, Capital Structure, SEC Filing, 8-K, Corporate Governance, Beneficial Ownership, Coastlands Capital Partners LP, Nasdaq Capital Market